Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 5/20 | 0.40 |
| ▸ | NPPA | P01160 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5702665 | 1.00 | MME (0.60) | MMEACEMMP1NPPAITGB1 | |
| SCHEMBL8336390 | 1.00 | MME (0.60) | MMEACEMMP1NPPAITGB1 | |
| SCHEMBL5702567 | 0.92 | MME (0.56) | MME | |
| SCHEMBL5702572 | 0.92 | MME (0.56) | MME | |
| SCHEMBL5702643 | 0.90 | MME (0.56) | MMEMMP1NPPA | |
| SCHEMBL8334290 | 0.90 | MME (0.50) | MMEACEMMP1ITGB1ITGA4 | |
| SCHEMBL5702538 | 0.90 | MME (0.57) | MMEMMP1ITGB1ITGA4KMT2A | |
| SCHEMBL5702593 | 0.90 | MME (0.49) | MMEACEMMP1NPPA | |
| SCHEMBL5702625 | 0.90 | MME (0.49) | MMEACEMMP1NPPA | |
| SCHEMBL5702547 | 0.88 | MME (0.72) | MMEACEMMP1NPPAITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | claimed |
| US-7045653-B2 | cyclopentyl substituted glutaramide derivatives; inhibitors of neutral endopeptidase which may be used to treat cardiovascular disorders, especially hypertension | PFIZER, INC. (US) | 2006-05-16 | — | — | US | claimed |
| EP-1581480-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS | Pfizer Limited (GB) | 2005-10-05 | — | — | EP | claimed |
| US-20050075392-A1 | Novel pharmaceuticals | DACK KEVIN NEIL (GB) | 2005-04-07 | — | — | US | claimed |
| WO-2004056750-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-7045653-B2 | cyclopentyl substituted glutaramide derivatives; inhibitors of neutral endopeptidase which may be used to treat cardiovascular disorders, especially hypertension | PFIZER, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1581480-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS | Pfizer Limited (GB) | 2005-10-05 | — | — | EP | disclosed |
| US-20050075392-A1 | Novel pharmaceuticals | DACK KEVIN NEIL (GB) | 2005-04-07 | — | — | US | disclosed |
| WO-2004056750-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075392-A1 | Novel pharmaceuticals | MME, ECE1, ECE2 | MME 1/4885ACE 8/4885MMP1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.